Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SGNTUC-019
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
- NCT04579380 ↗
- Active, not recruiting
- Seagen, a wholly owned subsidiary of Pfizer
- Deep
We haven't built an HCP commentary report on SGNTUC-019 (tucatinib plus trastuzumab; tucatinib plus trastuzumab plus fulvestrant in previously treated advanced solid tumors with HER2 alterations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SGNTUC-019 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 19 | |
| Podcasts | 3 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Uterine Neoplasms; Uterine Cervical Neoplasms; Biliary Tract Neoplasms; Urologic Neoplasms; Carcinoma, Non-Small-Cell Lung; HER2 Mutations Breast Neoplasms
- Interventions
- tucatinib; trastuzumab; fulvestrant
- Arms
- Tucatinib + Trastuzumab (+ Fulvestrant) · Experimental
- Enrollment
- 217
- Primary outcomes
- Confirmed Objective Response Rate (cORR) as Assessed by Investigator
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Start
- Jan 11, 2021
- Primary completion
- Nov 1, 2023
- Results posted
- Yes
- Registry record
- NCT04579380 · updated Aug 21, 2026
Publications
linked from the registry- Okines AFC, Curigliano G, Mizuno N, Oh DY, Rorive A, Soliman H, Takahashi S, Bekaii-Saab T, Burkard ME, Chung KY, Debruyne PR, Fox JR, Gambardella V, Gil-Martin M, Hamilton EP, Monk BJ, Nakamura Y, Nguyen D, O'Malley DM, Olawaiye AB, Pothuri B, Reck M, Sudo K, Sunakawa Y, Van Marcke C, Yu EY, Ramos J, Tan S, Bieda M, Stinchcombe TE, Pohlmann PR. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. Nat Med. 2025 Mar;31(3):909-916. doi: 10.1038/s41591-024-03462-0. Epub 2025 Jan 17. PubMed 39825152
- Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. J Clin Oncol. 2023 Dec 20;41(36):5569-5578. doi: 10.1200/JCO.23.00606. Epub 2023 Sep 26. PubMed 37751561